Novo to launch Ozempic pill for diabetes in second quarter of 2026 [BNN Bloomberg (Canada)]
Novo Nordisk A/S (NVO)
Last novo nordisk a/s earnings: 2/5 01:31 am
Check Earnings Report
US:NYSE Investor Relations:
novonordisk.com/investors.html
Company Research
Source: BNN Bloomberg
The company said the U.S. Food and Drug Administration has approved Ozempic tablets in 1.5 milligram, 4 milligram, and 9 milligram doses. The new Ozempic name is intended to help patients and health care professionals more easily recognize the available treatment options for type 2 diabetes, the company said. “Because Ozempic is so well known, people often ask whether there's an oral option for people with type 2 diabetes, without realizing Rybelsus has been available since 2019,” said Ed Cinca, senior vice president of marketing & patient solutions at Novo Nordisk. Semaglutide tablets at 3 mg, 7 mg, and 14 mg doses have been available under the brand name Rybelsus for diabetes. The pill is also approved to reduce the risk of certain cardiovascular conditions in adults with type 2 diabetes who are at high risk for these events. The FDA had approved the new doses based on a bioequivalence study and the clinical trial data for Rybelsus, Novo said. The Danish drugmaker expec
Show less
Read more
Impact Snapshot
Event Time:
NVO
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
NVO alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
NVO alerts
High impacting Novo Nordisk A/S news events
Weekly update
A roundup of the hottest topics
NVO
News
- Patient preference is leaning towards Eli Lilly's weight loss drugs, says Guggenheim's Fernandez [CNBC]CNBC
- Eli Lilly Soars, Novo Nordisk Plummets On GLP/Obesity Updates - Here's What To Do [Seeking Alpha]Seeking Alpha
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance]Yahoo! Finance
- Eli Lilly stock surges after company touts strong sales outlook as rival Novo Nordisk continues plunge [Yahoo! Finance Canada]Yahoo! Finance Canada
- Wegovy pill in high demand in weeks since launch, Novo Nordisk says [MSNBC.com]MSNBC.com
NVO
Earnings
- 2/3/26 - Beat
NVO
Sec Filings
- 2/4/26 - Form IRANNOTICE
- 2/4/26 - Form 20-F
- 2/4/26 - Form 6-K
- NVO's page on the SEC website